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Abstract. Pre-exposure prophylaxis (PrEP) consists in the use of an an-
tiretroviral medication to prevent the acquisition of HIV infection by uninfected
individuals and has recently demonstrated to be highly efficacious for HIV pre-
vention. We propose a new epidemiological model for HIV/AIDS transmission
including PrEP. Existence, uniqueness and global stability of the disease free
and endemic equilibriums are proved. The model with no PrEP is calibrated
with the cumulative cases of infection by HIV and AIDS reported in Cape
Verde from 1987 to 2014, showing that it predicts well such reality. An op-
timal control problem with a mixed state control constraint is then proposed
and analyzed, where the control function represents the PrEP strategy and the
mixed constraint models the fact that, due to PrEP costs, epidemic context
and program coverage, the number of individuals under PrEP is limited at each
instant of time. The objective is to determine the PrEP strategy that satisfies
the mixed state control constraint and minimizes the number of individuals
with pre-AIDS HIV-infection as well as the costs associated with PrEP. The
optimal control problem is studied analytically. Through numerical simula-
tions, we demonstrate that PrEP reduces HIV transmission significantly.
1. Introduction. The human immunodeficiency virus (HIV) is a retrovirus that
causes HIV infection and, over time, acquired immunodeficiency syndrome (AIDS)
[35]. The most significant advance in medical management of HIV infection has been
the treatment of patients with antiviral drugs, which can suppress HIV replication
to undetectable levels. Before 1996, few antiretroviral (ART) treatment options for
HIV infection existed. The treatment of HIV infection was revolutionized in the mid
1990s with the introduction of drug regimens that combine inhibitors of the reverse
transcriptase and protease and two of three essential enzymes of HIV. Combination
of antiretroviral drugs, dramatically suppresses viral replication and reduces the
HIV viral load to levels below the limits of detection of the most sensitive clinical
assays, resulting in a significant reconstitution of the immune system [4].
The Global AIDS Update 2016 of the Joint United Nations Programme on
HIV/AIDS, reports that the global coverage of ART therapy reached approximately
46% at the end of 2015. The gains in treatment are largely responsible for a 26%
decline in AIDS-related deaths globally since 2010, from an estimated 1.5 million
in 2010, to 1.1 million in 2015. Despite this significant achievement, there has not
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been a decrease in new infections since 2010, with more than 2 million new in-
fections reported in 2015 [33]. The World Health Organization’s (WHO) Global
Health Sector Strategy on HIV embraces innovation in the HIV response, recom-
mending, for example, that people at substantial risk of HIV infection should be
offered pre-exposure prophylaxis (PrEP) as an additional prevention choice, as part
of comprehensive prevention. PrEP is the use of an antiretroviral medication to
prevent the acquisition of HIV infection by uninfected individuals. Several trials
among men who have sex with men, people who inject drugs, transgender peo-
ple, women and serodiscordant couples (one partner is HIV-positive and the other
is HIV-negative) have shown that when PrEP is taken, it is an effective and safe
mechanism for preventing HIV-infection [36].
In [1], it is concluded that PrEP could prevent 2.7 to 3.2 million new cases of HIV
in sub-Saharan Africa over 10 years, if it is targeted to the highest risk groups, and
disinhibition could be prevented. In 2008, the authors of [14] claimed that PrEP
represents the most powerful available biologic intervention for HIV prevention. In
2016, WHO has welcomed a plan by the South African Ministry of Health to provide
immediate antiretroviral treatment to all sex workers with HIV, and to offer daily
oral PrEP to HIV-negative sex workers to prevent them from acquiring the infection
[41]. Following WHO, making PrEP drugs available for safe, effective prevention
outside the clinical trial setting is the current challenge.
Substantial gaps remain in understanding the trade-offs between the costs and
benefits of choosing alternative HIV prevention strategies, such as the initiation of
PrEP by high risk uninfected individuals [13]. Mathematical models of HIV that
include PrEP are scarce [6]. In [17], a mathematical model is used to estimate the
effects of early diagnosis, early treatment and PrEP, on the HIV epidemic in South
Korea over the next 40 years, as compared with the current situation. In [13], the
authors develop a mathematical model to simulate HIV incidence among men re-
siding in Los Angeles County, CA, aged between 15 to 65 years old, who have sex
with men. They claim that PrEP and Test-and-Treat yield the largest reductions
in HIV incidence, and are highly cost-effective. Another cost-effectiveness study
was done in [3] and the results showed that PrEP can be cost-saving if delivered to
individuals at increased risk of infection. In this paper, we propose a new mathe-
matical epidemiological model for HIV/AIDS transmission including PrEP, which
generalizes the HIV/AIDS sub-model recently proposed in [30].
First, we consider the mathematical model with no PrEP, calibrate the model
to the cumulative cases of infection by HIV and AIDS from 1987 to 2014 reported
in [25], and we show that the model predicts well the reality given in [25]. In this
model, the effective contact with people infected with HIV includes two modification
parameters that account for the relative infectiousness of individuals with AIDS
symptoms, in comparison to those infected with HIV with no AIDS symptoms [37],
and for partial restoration of the immune function of individuals with HIV infection
that use ART correctly [10]. It should be noted that the infectiousness of the HIV-
infected individuals under ART treatment is a controversial subject. HIV treatment
reduces the viral load in the blood, and also in other body fluids, such as semen and
vaginal fluid. However, not all people living with HIV who take HIV treatment and
have an undetectable viral load in the blood also have an undetectable viral load
in their other bodily fluids: see, e.g., [22] and references therein. In our paper, the
values considered for the modification parameters are based on two different research
studies: the first one is known as HPTN 052, where it was found that the risk of
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HIV transmission among heterosexual serodiscordant couples is 96% lower when the
HIV-positive partner is on treatment [9]; and the other one, where it was proved
that HIV-infected individuals under ART treatment have a very low probability
(assumed inferior to 0.04) of transmitting HIV [11]. We prove the global stability
of the endemic equilibrium and we provide numerical simulations, illustrating the
calibration of the model to the HIV/AIDS situation in Cape Verde.
In [23], the authors evaluate the effect of early HIV treatment and optimization
of care, HIV testing, condom distribution, and substance abuse treatment on HIV
incidence from 2011 to 2021, using Cape Verde as an example. However, they did
not include PrEP for HIV negative groups at risk as a possible prevention measure.
Here, we show that inclusion of PrEP can reduce significantly the HIV incidence.
We start by proving existence and global stability of the disease free equilibrium
of the HIV/AIDS-PrEP model. Moreover, we also prove existence of an unique
endemic equilibrium and the global stability for some specific relevant cases. It is
important, however, to highlight that PrEP is not for everyone [40]. Only people
who are HIV-negative and at very high risk for HIV infection should take PrEP.
Moreover, PrEP is highly expensive and it is still not approved in many countries,
e.g., by the European Medicines Agency (EMEA) [32]. Therefore, the number of
individuals that should take PrEP is limited at each instant of time. In order to
study this health public problem, we formulate an optimal control problem with a
mixed state control constraint.
Optimal control theory has been successfully applied to several epidemiological
models, e.g., dengue [27, 28], tuberculosis [12, 29], Ebola [16, 24], cholera [20], and
HIV/AIDS [26, 31]. However, we claim our work to be the first to apply opti-
mal control to an HIV/AIDS model with PrEP. More precisely, we consider the
HIV/AIDS-PrEP model and formulate an optimal control problem with the aim
to determine the PrEP strategy that satisfies the mixed state control constraint
and minimizes the number of individuals with pre-AIDS HIV-infection as well as
the costs associated with PrEP. We solve the optimal control problem and provide
numerical simulations, which show that it is possible to reduce the HIV incidence
through PrEP and having into consideration the limitations related to the imple-
mentation of PrEP (cost, epidemic context, program coverage and individual-level
adherence).
The paper is organized as follows. In Section 2, we consider the SICA model
for HIV/AIDS transmission proposed in [30] and prove the global stability of the
unique endemic equilibrium for the case when the associated AIDS-induced mortal-
ity is negligible. We calibrate the SICA model to the cumulative cases of infection
by HIV and AIDS from 1987 to 2014 in Cape Verde and show that it predicts well
this reality. In Section 3, we generalize the SICA model by including the possibility
of providing PrEP to susceptible individuals. We prove the existence and global
stability of the disease-free equilibrium for R0 < 1, where R0 denotes the basic
reproduction number, which is computed following [34]. We prove existence of an
unique endemic equilibrium point for R0 > 1 and its global stability for a negligible
AIDS-induced death rate and strict adherence to PrEP. Through numerical simula-
tions, we investigate the impact of PrEP in the reduction of HIV transmission. In
Section 4, we propose and analyze an optimal control problem with a mixed state
control constraint. Numerical simulations show that the extremal solutions combine
a reduction of HIV transmission with limited number of individuals under PrEP at
each instant of time. We end with Section 5 of conclusions and future work.
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2. The SICA model for HIV/AIDS transmission. In this section, we analyze
a mathematical model for HIV/AIDS transmission with varying population size in
a homogeneously mixing population, first proposed in [30], and prove the global
stability of the unique endemic equilibrium for the case when the associated AIDS-
induced mortality is negligible. The model subdivides human population into four
mutually-exclusive compartments: susceptible individuals (S); HIV-infected indi-
viduals with no clinical symptoms of AIDS (the virus is living or developing in the
individuals but without producing symptoms or only mild ones) but able to trans-
mit HIV to other individuals (I); HIV-infected individuals under ART treatment
(the so called chronic stage) with a viral load remaining low (C); and HIV-infected
individuals with AIDS clinical symptoms (A). The total population at time t, de-
noted by N(t), is given by N(t) = S(t) + I(t) +C(t) +A(t). Effective contact with
people infected with HIV is at a rate λ, given by
λ =
β
N
(I + ηC C + ηAA) ,
where β is the effective contact rate for HIV transmission. The modification pa-
rameter ηA ≥ 1 accounts for the relative infectiousness of individuals with AIDS
symptoms, in comparison to those infected with HIV with no AIDS symptoms. In-
dividuals with AIDS symptoms are more infectious than HIV-infected individuals
(pre-AIDS) because they have a higher viral load and there is a positive correlation
between viral load and infectiousness [37]. On the other hand, ηC ≤ 1 translates
the partial restoration of immune function of individuals with HIV infection that
use ART correctly [10]. All individuals suffer from natural death, at a constant rate
µ. We assume that HIV-infected individuals with and without AIDS symptoms
have access to ART treatment. HIV-infected individuals with no AIDS symptoms
I progress to the class of individuals with HIV infection under ART treatment C
at a rate φ, and HIV-infected individuals with AIDS symptoms are treated for HIV
at rate α. We also assume that an HIV-infected individual with AIDS symptoms A
that starts treatment moves to the class of HIV-infected individuals I, moving to
the chronic class C only if the treatment is maintained. HIV-infected individuals
with no AIDS symptoms I that do not take ART treatment progress to the AIDS
class A at rate ρ. Note that only HIV-infected individuals with AIDS symptoms A
suffer from an AIDS induced death, at a rate d. These assumptions are translated
in the following mathematical model:

S˙(t) = Λ− β(I(t)+ηC C(t)+ηAA(t))
N(t) S(t)− µS(t),
I˙(t) = β(I(t)+ηC C(t)+ηAA(t))
N(t) S(t)− (ρ+ φ+ µ)I(t) + αA(t) + ωC(t),
C˙(t) = φI(t) − (ω + µ)C(t),
A˙(t) = ρ I(t)− (α+ µ+ d)A(t).
(1)
We consider the biologically feasible region
Ω = {(S, I, C,A) ∈ R4+ : N ≤ Λ/µ}. (2)
Using a standard comparison theorem (see [18]), one can easily show that N(t) ≤ Λ
µ
if N(0) ≤ Λ
µ
. Thus, the region Ω defined by (2) is positively invariant. Hence, it is
sufficient to consider the dynamics of the flow generated by (1) in Ω. In this region,
the model is epidemiologically and mathematically well posed in the sense of [15].
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In other words, every solution of model (1) with initial conditions in Ω remains in
Ω for all t > 0. For this reason, the dynamics of the model is considered in Ω.
Theorem 2.1 (See [30]). The population N(t) is uniformly persistent, that is,
lim inf
t→∞
N(t) ≥ ε
with ε > 0 not depending on the initial data.
Model (1) has a disease-free equilibrium, given by
Σ0 =
(
S0, I0, C0, A0
)
=
(
Λ
µ
, 0, 0, 0
)
.
Following [34], the basic reproduction number R0 for model (1), which represents
the expected average number of new HIV infections produced by a single HIV-
infected individual when in contact with a completely susceptible population, is
given by
R0 =
β (ξ2 (ξ1 + ρ ηA) + ηC φ ξ1)
µ (ξ2 (ρ+ ξ1) + φ ξ1 + ρ d) + ρω d
=
N
D
, (3)
where ξ1 = α+ µ+ d, ξ2 = ω + µ and ξ3 = ρ+ φ+ µ.
Lemma 2.2 (See [30]). The disease free equilibrium Σ0 is locally asymptotically
stable if R0 < 1, and unstable if R0 > 1.
Theorem 2.3 (See [30]). The disease free equilibrium Σ0 is globally asymptotically
stable for R0 < 1.
To find conditions for the existence of an equilibrium for which HIV is endemic
in the population (i.e., at least one of I∗, C∗ or A∗ is nonzero), denoted by Σ+ =
(S∗, I∗, C∗, A∗), the equations in (1) are solved in terms of the force of infection at
the steady-state λ∗, given by
λ∗ =
β (I∗ + ηC C
∗ + ηAA
∗)
N∗
. (4)
Setting the right hand side of the equations of the model to zero, and noting that
λ = λ∗ at equilibrium gives
S∗ =
Λ
λ∗ + µ
, I∗ = −
λ∗Λξ1ξ2
D
, C∗ = −
φλ∗Λξ1
D
, A∗ = −
ρ1λ
∗Λξ2
D
(5)
with D = −(λ∗ + µ)(µ (ξ2(ρ+ ξ1) + ξ1φ+ ρd) + ρωd), we use (5) in the expression
for λ∗ in (4) to show that the nonzero (endemic) equilibrium of the model satisfies
λ∗ = −µ(1−R0).
The force of infection at the steady-state λ∗ is positive only if R0 > 1. Thus, the
existence and uniqueness of the endemic equilibrium follows.
Lemma 2.4 (See [30]). The model (1) has a unique endemic equilibrium whenever
R0 > 1.
Remark 1. The expression of the endemic equilibrium of model (1) is given by
S∗ =
Λ(ρdξ2 −D)
µ(ρdξ2 −N )
, I∗ =
Λξ1ξ2(D −N )
D(ρdξ2 −N )
,
C∗ =
Λφξ1(D −N )
D(ρdξ2 −N )
, A∗ =
Λρξ2(D −N )
D(ρdξ2 −N )
.
Theorem 2.5 (See [30]). The endemic equilibrium Σ+ is locally asymptotically
stable for R0 near 1.
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2.1. Global stability of the endemic equilibrium for negligible AIDS-
induced death rate (d = 0). In this section, we investigate the global stability
of the endemic equilibrium of model (1) for the case when the associated AIDS-
induced mortality is negligible (d = 0). Adding the equations of the model (1),
with d = 0, gives N˙ = Λ − µN , so that N → Λ
µ
as t → ∞. Thus, Λ
µ
is an upper
bound of N(t) provided that N(0) ≤ Λ
µ
. Further, if N(0) > Λ
µ
, then N(t) decreases
to this level. Using N = Λ
µ
in the force of infection λ = β
N
(I + ηC C + ηAA) gives
a limiting (mass action) system (see, e.g., [2]). Then, the force of infection becomes
λ = β1 (I + ηC C + ηAA) , where β1 =
βµ
Λ
.
Therefore, we consider the model

S˙(t) = Λ− β1 (I(t) + ηC C(t) + ηAA(t))S(t)− µS(t),
I˙(t) = β1 (I(t) + ηC C(t) + ηAA(t))S(t)− ξ3I(t) + αA(t) + ωC(t),
C˙(t) = φI(t)− ξ2C(t),
A˙(t) = ρ I(t)− ξ1A(t),
(6)
where ξ1 = α + µ. The model (6) has a unique endemic equilibrium given by
Σ˜+ = Σ+|d=0, whenever R˜0 = R0|d=0 > 1. Let us define
Ω0 = {(S, I, C,A) ∈ Ω : I = C = A = 0}.
Theorem 2.6. The endemic equilibrium Σ˜+ of model (6) is globally asymptotically
stable in Ω\Ω0 whenever R˜0 > 1.
Proof. Consider the following Lyapunov function:
V = (S − S∗ ln(S)) + (I − I∗ ln(I)) +
ω
ξ2
(C − C∗ ln(C)) +
α
ξ1
(A−A∗ ln(A)) . (7)
Differentiating V with respect to time gives
V˙ =
(
1−
S∗
S
)
S˙ +
(
1−
I∗
I
)
I˙ +
ω
ξ2
(
1−
C∗
C
)
C˙ +
α
ξ1
(
1−
A∗
A
)
A˙.
Substituting the expressions for the derivatives in V˙ , it follows from (1) that
V˙ =
(
1−
S∗
S
)
[Λ− β1 (I + ηC C + ηAA)S − µS]
+
(
1−
I∗
I
)
[β1 (I + ηC C + ηAA)S − ξ3I + αA+ ωC]
+
ω
ξ2
(
1−
C∗
C
)
[φI − ξ2C] +
α
ξ1
(
1−
A∗
A
)
[ρI − ξ1A] .
(8)
Using relation Λ = β1 (I
∗ + ηC C
∗ + ηAA
∗)S∗+µS∗, we have from the first equation
of system (6) at steady-state that (8) can be written as
V˙ =
(
1−
S∗
S
)
[β1 (I
∗ + ηC C
∗ + ηAA
∗)S∗ + µS∗ − β1 (I + ηC C + ηAA)S − µS]
+
(
1−
I∗
I
)
[β1 (I + ηC C + ηAA)S − ξ3I + αA+ ωC]
+
ω
ξ2
(
1−
C∗
C
)
[φI − ξ2C] +
α
ξ1
(
1−
A∗
A
)
[ρI − ξ1A] ,
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which can then be simplified to
V˙ =
(
1−
S∗
S
)
β1I
∗S∗ + µS∗
(
2−
S
S∗
−
S∗
S
)
− β1IS + β1IS
∗
+ β1(ηCC
∗ + ηAA
∗)S∗ − β1(ηCC + ηAA)S −
S∗
S
β1(ηCC
∗ + ηAA
∗)S∗
+ S∗β1(ηCC + ηAA) +
(
1−
I∗
I
)
[β1 (I + ηC C + ηAA)S − ξ3I + αA+ ωC]
+
ω
ξ2
(
1−
C∗
C
)
[φI − ξ2C] +
α
ξ1
(
1−
A∗
A
)
[ρI − ξ1A] .
Using the relations at the steady state
ξ3I
∗ = β1(I
∗ + ηCC
∗ + ηAA
∗)S∗ + αA∗ + ωC∗, ξ2C
∗ = φI∗, ξ1A
∗ = ρI∗,
and after some simplifications, we have
V˙ =(β1I
∗S∗ + µS∗)
(
2−
S
S∗
−
S∗
S
)
+ β1S
∗ (ηCC
∗ + ηAA
∗)
(
1−
S∗
S
)
+ β1S
∗ (ηCC
∗ + ηAA
∗)
(
1−
I
I∗
)
+ β1S
∗ (ηCC + ηAA)
(
1−
I∗
I
S
S∗
)
+ αA∗
(
1−
A
A∗
I∗
I
)
+ ωC∗
(
1−
C
C∗
I∗
I
)
+
ωφ
ξ2
I∗
(
1−
I
I∗
C∗
C
)
+
αρ
ξ1
I∗
(
1−
I
I∗
A∗
A
)
.
The terms between the larger brackets are less than or equal to zero by a well-
known inequality: the geometric mean is less than or equal to the arithmetic mean.
The equality dV
dt
= 0 holds if and only if (S, I, C,A) take the equilibrium val-
ues (S∗, I∗, C∗, A∗). Therefore, by LaSalle’s Invariance Principle [19], the endemic
equilibrium Σ+ is globally asymptotically stable.
We conjecture that the endemic equilibrium for positive AIDS-induced death
rate (d > 0) is globally asymptotically stable. This remains an open question.
2.2. Case study for Cape Verde. In this section, we calibrate model (1) to the
cumulative cases of infection by HIV and AIDS in Cape Verde from 1987 to 2014.
We show that our model predicts well this reality. In Table 1, the cumulative cases
of infection by HIV and AIDS in Cape Verde are depicted for the years 1987–2014
[25]. We consider the initial conditions (9) based on [25, 38]:
S0 = S(0) = 323911 , I0 = I(0) = 61 , C0 = C(0) = 0 , A0 = A(0) = 0. (9)
We borrow the parameter values φ = 1, ρ = 0.1, α = 0.33 and ω = 0.09 from
[30]. Following the World Bank data [38, 42], the natural death rate is assumed
to take the value µ = 1/69.54. The recruitment rate Λ = 13045 was estimated
in order to approximate the values of the total population of Cape Verde given
in Table 1. See Figure 1, were we can observe that model (1) fits well the total
population of Cape Verde. The AIDS induced death rate is assume to be d = 1
based on [39]. Two cases are considered: ηC = 0.04, based on a research study
known as HPTN 052, where it is found that the risk of HIV transmission among
heterosexual serodiscordant couples is 96% lower when the HIV-positive partner is
on treatment [9]; and ηC = 0.015, which means that HIV-infected individuals under
ART treatment have a very low probability of transmitting HIV, based on [11]. For
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Table 1. Cumulative cases of infection by HIV/AIDS and total
population in Cape Verde in the period 1987–2014 [25, 42].
Year 1987 1988 1989 1990 1991 1992 1993
HIV/AIDS 61 107 160 211 244 303 337
Population 323972 328861 334473 341256 349326 358473 368423
Year 1994 1995 1996 1997 1998 1999 2000
HIV/AIDS 358 395 432 471 560 660 779
Population 378763 389156 399508 409805 419884 429576 438737
Year 2001 2002 2003 2004 2005 2006 2007
HIV/AIDS 913 1064 1233 1493 1716 2015 2334
Population 447357 455396 462675 468985 474224 478265 481278
Year 2008 2009 2010 2011 2012 2013 2014
HIV/AIDS 2610 2929 3340 3739 4090 4537 4946
Population 483824 486673 490379 495159 500870 507258 513906
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Figure 1. Model (1) fitting the total population of Cape Verde
between 1987 and 2014 [25, 42]. The l2 norm of the difference
between the real total population of Cape Verde and our prediction
gives an error of 1.9% of individuals per year with respect to the
total population of Cape Verde in 2014.
the modification parameter ηA ≥ 1 that accounts for the relative infectiousness of
individuals with AIDS symptoms, in comparison to those infected with HIV with no
AIDS symptoms, we assume ηA = 1.3 and ηA = 1.35, based in [37]. We estimated
the value of the HIV transmission rate β for (ηC , ηA) = (0.04, 1.35) equal to 0.695
and for (ηC , ηA) = (0.015, 1.3) equal to 0.752, and show that the model (1) predicts
well the reality of Cape Verde for these parameter values: see Figure 2. All the
considered parameter values are resumed in Table 2.
For the triplets (β, ηC , ηA) = (0.752, 0.015, 1.3) and (β, ηC , ηA) = (0.695, 0.04, 1.35),
and the other parameter values from Table 2, we have that the basic reproduction
number is given by R0 = 4.0983 and R0 = 4.5304, respectively.
MODELING AND OPTIMAL CONTROL OF HIV/AIDS 9
time (years)
0 5 10 15 20 25
cu
m
u
la
tiv
e 
H
IV
 a
nd
 A
ID
S 
ca
se
s
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
real data
model
(a) (β, ηC , ηA) = (0.752, 0.015, 1.3)
time (years)
0 5 10 15 20 25
cu
m
u
la
tiv
e 
H
IV
 a
nd
 A
ID
S 
ca
se
s
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
real data
model
(b) (β, ηC , ηA) = (0.695, 0.04, 1.35)
Figure 2. Model (1) fitting the data of cumulative cases of HIV
and AIDS infection in Cape Verde between 1987 and 2014 [25]. The
l2 norm of the difference between the real data and the cumulative
cases of infection by HIV/AIDS given by model (1) gives, in both
cases, an error of 0.03% of individuals per year with respect to the
total population of Cape Verde in 2014.
Table 2. Parameters of the HIV/AIDS model (1) for Cape Verde.
Symbol Description Value Reference
N(0) Initial population 323972 [38]
Λ Recruitment rate 13045 [38]
µ Natural death rate 1/69.54 [38]
β HIV transmission rate 0.752 Estimated
ηC Modification parameter 0.015, 0.04 Assumed
ηA Modification parameter 1.3, 1.35 Assumed
φ HIV treatment rate for I individuals 1 [30]
ρ Default treatment rate for I individuals 0.1 [30]
α AIDS treatment rate 0.33 [30]
ω Default treatment rate for C individuals 0.09 [30]
d AIDS induced death rate 1 [39]
3. The SICAE model. Now we generalize the model proposed in Section 2 by
adding the possibility of providing PrEP to susceptible individuals. We add a
class of individuals to the total population N , denoted by E, which represents
the individuals that are under PrEP. The proportion of susceptible individuals that
takes PrEP is denoted by ψ. We assume that PrEP is effective so that all susceptible
individuals under PrEP treatment are transferred to class E. The individuals that
stop PrEP become susceptible individuals again, at a rate θ. Individuals under
PrEP may suffer of natural death at a rate µ. The model is given by the following
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system of ordinary differential equations:

S˙(t) = Λ− β(I(t)+ηC C(t)+ηAA(t))
N(t) S(t)− µS(t)− ψS(t) + θE(t),
I˙(t) = β(I(t)+ηC C(t)+ηAA(t))
N(t) S(t)− (ρ+ φ+ µ)I(t) + αA(t) + ωC(t),
C˙(t) = φI(t)− (ω + µ)C(t),
A˙(t) = ρ I(t)− (α+ µ+ d)A(t),
E˙(t) = ψS(t)− (µ+ θ)E(t).
(10)
We consider the biologically feasible region
ΩP =
{
(S, I, C,A,E) ∈ R5+0 : S ≤
(θ + µ) Λ
µ (θ + ψ + µ)
, E ≤
ψΛ
µ (θ + ψ + µ)
, N ≤
Λ
µ
}
.
3.1. Existence and stability of the disease-free equilibrium. Model (10) has
a disease-free equilibrium, given by
Σ0 =
(
S0, I0, C0, A0, E0
)
=
(
(θ + µ) Λ
µ (θ + ψ + µ)
, 0, 0, 0,
ψΛ
µ (θ + ψ + µ)
)
. (11)
The linear stability of Σ0 can be obtained using the next-generation method on
system (10). Following [34], the basic reproduction number for model (10) is given
by (3), that is,
R0 =
β (ξ2 (ξ1 + ρ ηA) + ηC φ ξ1)
µ (ξ2 (ρ+ ξ1) + φ ξ1 + ρ d) + ρω d
=
N
D
,
where ξ1 = α + µ + d, ξ2 = ω + µ, and ξ3 = ρ+ φ + µ. Thus, from Theorem 2 of
[34], the following result is established.
Lemma 3.1. The disease free equilibrium Σ0 of model (10), given by (11), is locally
asymptotically stable if R0 < 1, and unstable if R0 > 1.
Biologically speaking, Lemma 3.1 implies that HIV infection can be eliminated
from the community (when R0 < 1) if the initial size of the population is in the basin
of attraction of Σ0. To ensure that elimination of HIV infection is independent of the
initial size of the population, it is necessary to show that the disease free equilibrium
is globally asymptotically stable [21]. This is obtained in what follows.
Theorem 3.2. The disease free equilibrium Σ0 is globally asymptotically stable for
R0 < 1.
Proof. Consider the following Lyapunov function:
V =(ξ1ξ2 + ξ1φηC + ξ2ρηA) I + (ξ1ω + ξ1ξ3ηC + ρηAω − ηCρα)C
+ (αξ2 + ξ2ξ3ηA + φηCα− φηAω)A.
The time derivative of V computed along the solutions of (1) is given by
V˙ = (ξ1ξ2 + ξ1φηC + ξ2ρηA) I˙ + (ξ1ω + ξ1ξ3ηC + ρηAω − ηCρα) C˙
+ (αξ2 + ξ2ξ3ηA + φηCα− φηAω) A˙
= (ξ1ξ2 + ξ1φηC + ξ2ρηA)
(
β
N
(I + ηC C + ηAA)S − ξ3I + αA + ωC
)
+ (ξ1ω + ξ1ξ3ηC + ρηAω − ηCρα) (φI − ξ2C)
+ (αξ2 + ξ2ξ3ηA + φηCα− φηAω) (ρ I − ξ1A) .
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After some simplifications, we have
V˙ = (ξ1ξ2 + ξ1φηC + ξ2ρηA)
βIS
N
+ (−ξ1ξ2ξ3 + ξ1ωφ+ αξ2ρ)I
+ ηC(ξ1ξ2 + ξ1φηC + ξ2ρηA)
βCS
N
+ ηC(−ξ1ξ3ξ2 + ξ1φω + ραξ2)C
+ ηA(ξ1ξ2 + ξ1φηC + ξ2ρηA)
βAS
N
+ ηA(−ξ2ξ3ξ1 + φωξ1 + ξ2ρα)A
= D
(
R0
S
N
− 1
)
I + ηCD
(
R0
S
N
− 1
)
C + ηAD
(
R0
S
N
− 1
)
A
≤ D(R0 − 1)I + ηCD(R0 − 1)C + ηAD(R0 − 1)A (becauseS ≤ N in Ω)
≤ 0 for R0 < 1.
Because all model parameters are nonnegative, it follows that V˙ ≤ 0 for R0 < 1
with V˙ = 0 if, and only if, I = C = A = 0. Substituting (I, C,A) = (0, 0, 0) into
the equations for S and E in system (10) shows, respectively, that S → S0 and
E → E0 as t → ∞. Thus, it follows from LaSalle’s Invariance Principle [19] that
every solution of system (10) with initial conditions in Ω approaches the disease
free equilibrium Σ0 as t→∞ whenever R0 < 1.
The epidemiological significance of Theorem 3.2 is that HIV infection will be
eliminated from the population if the threshold quantity, R0, can be brought to a
value less than unity.
3.2. Existence and stability of the endemic equilibrium. The unique en-
demic equilibrium of model (10) exists whenever R0 > 1 and is given by
S∗ =
Λ ξ4 (ξ1(φ+ ξ2) + ρξ2)
F
, I∗ =
−ξ4 Λξ1ξ2(D −N )
DF
,
C∗ =
−ξ4 Λφξ1(D −N )
DF
,
A∗ =
−ξ4 Λρξ2(D −N )
DF
, E∗ =
ψΛ (ξ1(φ+ ξ2) + ρξ2)
F
,
where F = (N −ρdξ2)θ+(D−ρdξ2)ψ−µ(ρdξ2−N ) and ξ4 = θ+µ. We investigate
the global stability of the endemic equilibrium of model (10) for the case when
the associated AIDS-induced mortality is negligible (d = 0) and there is a strict
adherence to PrEP, that is, θ = 0. Adding the equations of model (10) with d = 0
and θ = 0 gives N˙ = Λ − µN , so that N → Λ
µ
as t → ∞. Thus, Λ
µ
is an upper
bound of N(t), provided N(0) ≤ Λ
µ
. Further, if N(0) > Λ
µ
, then N(t) decreases to
this level. Using N = Λ
µ
in the force of infection λ = β
N
(I + ηC C + ηAA) gives a
limiting (mass action) system. Then, the force of infection becomes
λ = β1 (I + ηC C + ηAA) , where β1 =
βµ
Λ
.
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Therefore, we consider the following model:


S˙(t) = Λ− β1 (I(t) + ηC C(t) + ηAA(t))S(t)− (µ+ ψ)S(t),
I˙(t) = β1 (I(t) + ηC C(t) + ηAA(t))S(t)− ξ3I(t) + αA(t) + ωC(t),
C˙(t) = φI(t)− ξ2C(t),
A˙(t) = ρ I(t)− ξ1A(t),
E˙(t) = ψS(t)− µE(t).
(12)
For system (12), the basic reproduction number is given by R0 =
ΛN1
(µ+ψ)D with
N1 = β1 (ξ2 (ξ1 + ρ ηA) + ηC φ ξ1). When R0 > 1, system (12) has a unique endemic
equilibrium Σ˜+ = (S˜, I˜, C˜, A˜, E˜) given by
S˜ =
µ (ξ1(φ+ ξ2) + ρξ2)
β1(ξ1(ξ2 + ηCφ) + ηAρξ2)
, I˜ =
ξ1ξ2(N −D)
D1
,
C˜ =
φξ1(N −D)
D1
, A˜ =
ρξ2(N −D)
D1
, E˜ =
ψ (ξ1(φ+ ξ2) + ρξ2)
β1(ξ1(ξ2 + ηCφ) + ηAρξ2)
,
(13)
where D1 = β1µ(ρξ2+ξ1(φ+ξ2))(ξ1(ξ2+ηCφ)+ηAρξ2). Since E does not appear in
the first four equations of system (12), we only need to consider the reduced system


S˙(t) = Λ− β1 (I(t) + ηC C(t) + ηAA(t))S(t)− (µ+ ψ)S(t),
I˙(t) = β1 (I(t) + ηC C(t) + ηAA(t))S(t)− ξ3I(t) + αA(t) + ωC(t),
C˙(t) = φI(t)− ξ2C(t),
A˙(t) = ρ I(t)− ξ1A(t).
(14)
Whenever R0 > 1, system (14) has a unique endemic equilibrium Σ1 = (S˜, I˜, C˜, A˜)
with S˜, I˜, C˜ and A˜ defined by (13). Consider the Lyapunov function (7) given by
V = (S − S∗ ln(S)) + (I − I∗ ln(I)) +
ω
ξ2
(C − C∗ ln(C)) +
α
ξ1
(A−A∗ ln(A)) .
Differentiating V with respect to time gives
V˙ =
(
1−
S∗
S
)
S˙ +
(
1−
I∗
I
)
I˙ +
ω
ξ2
(
1−
C∗
C
)
C˙ +
α
ξ1
(
1−
A∗
A
)
A˙.
Substituting the expressions for the derivatives in V˙ , it follows from (12) that
V˙ =
(
1−
S∗
S
)
[Λ− β1 (I + ηC C + ηAA)S − µS − ψS]
+
(
1−
I∗
I
)
[β1 (I + ηC C + ηAA)S − ξ3I + αA+ ωC]
+
ω
ξ2
(
1−
C∗
C
)
[φI − ξ2C] +
α
ξ1
(
1−
A∗
A
)
[ρI − ξ1A] .
(15)
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Using relation Λ = β1 (I
∗ + ηC C
∗ + ηAA
∗)S∗ + µS∗ + ψS∗, we have from the first
equation of system (12) at steady-state that (15) can be written as
V˙ =
(
1−
S∗
S
)[
β1 (I
∗ + ηC C
∗ + ηAA
∗)S∗ + µS∗ + ψS∗
− β1 (I + ηC C + ηAA)S − µS − ψS
]
+
(
1−
I∗
I
)
[β1 (I + ηC C + ηAA)S − ξ3I + αA+ ωC]
+
ω
ξ2
(
1−
C∗
C
)
[φI − ξ2C] +
α
ξ1
(
1−
A∗
A
)
[ρI − ξ1A] ,
which can be simplified to
V˙ =
(
1−
S∗
S
)
β1I
∗S∗ + µS∗
(
2−
S
S∗
−
S∗
S
)
+ ψS∗
(
2−
S
S∗
−
S∗
S
)
+ β1IS
∗
+ β1S
∗(ηCC
∗ + ηAA
∗)
(
1−
S∗
S
)
+ S∗β1(ηCC + ηAA)− ξ3I +
ω
ξ2
φI +
α
ξ1
ρI
−
I∗
I
[β1 (I + ηC C + ηAA)S − ξ3I + αA + ωC]
−
ω
ξ2
C∗
C
[φI − ξ2C]−
α
ξ1
A∗
A
[ρI − ξ1A] .
Using the relations
ξ3I
∗ = β1(I
∗ + ηCC
∗ + ηAA
∗)S∗ + αA∗ + ωC∗, ξ2C
∗ = φI∗, ξ1A
∗ = ρI∗
at the steady state, after some simplifications we have
V˙ =β1I
∗S∗
(
1−
S∗
S
)
+ µS∗
(
2−
S
S∗
−
S∗
S
)
+ ψS∗
(
2−
S
S∗
−
S∗
S
)
+ β1S
∗(ηCC
∗ + ηAA
∗)
(
1−
S∗
S
)
+ β1S
∗(ηCC
∗ + ηAA
∗)
(
1−
I
I∗
)
+ S∗β1(ηCC + ηAA)
(
1−
I∗
I
S
S∗
)
+ αA∗
(
1−
A
A∗
I∗
I
)
+ ωC∗
(
1−
C
C∗
I∗
I
)
+
ωφ
ξ2
I∗
(
1−
I
I∗
C∗
C
)
+
αρ
ξ1
I∗
(
1−
I
I∗
A∗
A
)
.
The terms between the larger brackets are less than or equal to zero because the
geometric mean is less than or equal to the arithmetic mean. Equality dV
dt
= 0
holds if and only if S = S∗, I = I∗, C = C∗ and A = A∗. By LaSalle’s Invariance
Principle [19], every solution to the equations in model (14) with initial conditions
in
{
(S, I, C,A) ∈ R4+0 : S ≤
Λ
ψ+µ , N ≤
Λ
µ
}
\ {S = I = C = A} approaches the en-
demic equilibrium Σ˜+, which implies that the endemic equilibrium Σ˜+ of system
(13) is globally asymptotically stable on ΩP \ΩP0, where ΩP0 = {(S, I, C,A) ∈ ΩP :
I = C = A = 0}. We have just proved the following result.
Theorem 3.3. The endemic equilibrium Σ˜+ of model (12) is globally asymptotically
stable in ΩP \ΩP0 whenever R0 > 1.
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A generalization of Theorem 3.3 to the case d > 0 and θ > 0 remains an open
question.
3.3. Numerical simulations. In this section, we investigate the impact of PrEP
in the reduction of HIV transmission. We assume that the total population is
constant, that is, Λ = µN with µ = 1/69.54 and d = 0. The initial conditions are
given by
S(0) = 10000, I(0) = 200, C(0) = 0, A(0) = 0 and E(0) = 0. (16)
We start our numerical simulations assuming that 10 per cent of the susceptible in-
dividuals take PrEP, that is, ψ = 0.1 and the default rate takes the value θ = 0.001.
Consider β = 0.582, ηC = 0.04, ηA = 1.35, and that the parameters ω, ρ, φ
and α take the values of Table 2. We compare the case (ψ, θ) = (0.1, 0.001) with
(ψ, θ) = (0, 0) for t ∈ [0, tf ], tf = 25 years, where (ψ, θ) = (0, 0) means that no sus-
ceptible individual was under PrEP. From Figure 3, we observe that PrEP reduces
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Figure 3. Top left: cumulative HIV and AIDS cases. Top right:
pre-AIDS HIV infected individuals I. Bottom left: HIV-infected in-
dividuals under ART treatment C. Bottom right: HIV-infected in-
dividuals with AIDS symptoms A. Expression “with PrEP” refers
to the case (ψ, θ) = (0.1, 0.001) and “no PrEP” refers to the case
(ψ, θ) = (0, 0).
the number of individuals with HIV infection. In fact, for (ψ, θ) = (0.1, 0.001), we
have S(25) ≃ 1687, I(25) ≃ 67, C(25) ≃ 626, A(25) ≃ 20 and E(25) = 7800. It is
important to note that I(t) is a decreasing function for all t ∈ [0, 25] and that the
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maximum value for the number of HIV-infected individuals with AIDS symptoms
is less than 22 for t ∈ [0, 25]. On the other hand, at the end of the 25 years, the
number of individuals that are taking PrEP is equal to 7800, which is highly expen-
sive (the PrEP drug costs between $8,000 and $14,000 per year for each individual).
Therefore, it is of most importance to establish what is the optimal proportion of
susceptible individuals that should take PrEP, taking into consideration its costs.
In Section 4, we formulate this problem mathematically, using the theory of optimal
control, and we study it both analytically and numerically.
4. Optimal control problem with a mixed state control constraint. Sub-
stantial gaps remain in understanding the trade-offs between costs and benefits of
choosing alternative HIV prevention strategies, such as the initiation of PrEP by
high risk uninfected individuals [13]. Following WHO, making PrEP drugs avail-
able for safe, effective prevention outside the clinical trial setting is the current
challenge. However, it is important to highlight and recall that PrEP is not for
everyone: only people who are HIV-negative and at very high risk for HIV infec-
tion should take PrEP [40]. Moreover, PrEP is highly expensive and it is still not
approved in many countries like, for example, by the European Medicines Agency
(EMEA) [32]. Therefore, the number of individuals that should take PrEP is lim-
ited at each instant of time for a fixed interval of time [0, tf ]. In order to study
this health public problem, from an optimal point of view, we formulate an optimal
control problem with a mixed state control constraint. For the usefulness of such
problems in epidemiology see, e.g., [5]. We consider the model with PrEP (10) and
formulate an optimal control problem with the aim to determine the PrEP strategy
ψ that minimizes the number of individuals with pre-AIDS HIV-infection I as well
as the costs associated with PrEP. We assume that the fraction of individuals that
takes PrEP, at each instant of time, is a control function, that is, ψ ≡ u(t) with
t ∈ [0, tf ], and that the total population N is constant: the recruitment rate is
proportional to the natural death rate, Λ = µN , and there are no AIDS-induced
deaths (d = 0). Precisely, we consider the model with control u(t) given by

S˙(t) = µN − β
N
(I(t) + ηC C(t) + ηAA(t))S(t)− µS(t)− S(t)u(t) + θE(t),
I˙(t) = β
N
(I(t) + ηC C(t) + ηAA(t))S(t)− (ρ+ φ+ µ)I(t) + αA(t) + ωC(t),
C˙(t) = φI(t) − (ω + µ)C(t),
A˙(t) = ρ I(t)− (α+ µ)A(t),
E˙(t) = S(t)u(t)− (µ+ θ)E(t)
(17)
and formulate an optimal control problem with the aim to determine the PrEP
strategy u over a fixed interval of time [0, tf ] that minimizes the cost functional
J(u) =
∫ tf
0
[
w1I(t) + w2u
2(t)
]
dt, (18)
where the constants w1 and w2 represent the weights associated with the number
of HIV infected individuals I and on the cost associated with the PrEP prevention
treatment, respectively. It is assumed that the control function u takes values
between 0 and 1. When u(t) = 0, no susceptible individual takes PrEP at time t; if
u(t) = 1, then all susceptible individuals are taking PrEP at time t. Let ϑ denote
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the total number of susceptible individuals under PrEP for a fixed time interval
[0, tf ]. This constraint is represented by
S(t)u(t) ≤ ϑ , ϑ ≥ 0 , for almost all t ∈ [0, tf ] , (19)
which should be satisfied at almost every instant of time during the whole PrEP
program. Let
x(t) = (x1(t), . . . , x5(t)) = (S(t), I(t), C(t), A(t), E(t)) ∈ R
5.
The optimal control problem consists to find the optimal trajectory x˜, associated
with the control u˜, satisfying the control system (17), the initial conditions (16),
x(0) = (x10, x20, x30, x40, x50), with x10 ≥ 0, x20 ≥ 0, x30 ≥ 0, x40 ≥ 0, x50 ≥ 0,
the constraint (19), and where the control u˜ ∈ Ω minimizes the objective functional
(18) with
Ω =
{
u(·) ∈ L∞(0, tf) | 0 ≤ u(t) ≤ 1
}
. (20)
The control system can be rewritten in the following way:
dx(t)
dt
= f(x(t)) +Ax(t) +Bx(t)u(t)
with
A =


−µ 0 0 0 0
0 −ρ− φ− µ ω α 0
0 φ −ω − µ 0 0
0 ρ 0 −α− µ 0
0 0 0 0 −µ− θ


and
B = (b Z) ,
where b = (−1 0 0 0 1)T and Z = 0 with 0 the 5× 4 null matrix and f = (f1 f2 0 0 0)
with
f1 = µN −
β
N
(I(t) + ηC C(t) + ηAA(t))S(t)
and
f2 =
β
N
(I(t) + ηC C(t) + ηAA(t))S(t).
It follows from Theorem 23.11 in [7] that problem (17)–(20) has a solution (see also
[5]). Let (x˜, u˜) denote such solution. To determine it, we apply the Pontryagin
Maximum Principle (see, e.g., Theorem 7.1 in [8]): there exist multipliers λ0 ≤ 0,
λ ∈ AC([0, tf ];R5), and ν ∈ L1([0, tf ];R), such that
• min{|λ(t)| : t ∈ [0, tf ]} > λ0 (nontriviality condition);
• dλ(t)
dt
= −∂H
∂x
(x˜(t), u˜(t), λ0, λ(t), ν(t)) (adjoint system);
• λ(t)Bx˜(t) + ν(t)x˜1(t) + λ0w2u˜2(t) ∈ N[0,1](u˜(t)) a.e. and
H(x˜(t), u˜(t), λ0, λ(t), ν(t)) ≤ H(x˜(t), v, λ0, λ(t), ν(t)) , ∀v ∈ [0, 1] : x˜1(t)v ≤ ϑ
(minimality condition);
• ν(t)(x˜1(t)u˜(t)− ϑ) = 0 and ν(t) ≤ 0 a.e.
• λ(tf ) = (0, . . . , 0) (transversality conditions);
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where the Hamiltonian H for problem (17)–(20) is defined by
H(x, u, λ0, λ, ν) = λ0
(
w1x2 + w2u
2
)
+ λ (f(x) +Ax+Bxu) + ν(Su− ϑ)
and N[0,1](u˜(t)) stands for the normal cone from convex analysis to [0, 1] at the
optimal control u˜(t) (see, e.g., [7]). The optimal solution (x˜, u˜) is normal (see [5]
for details), so we can choose λ0 = 1. The unique optimal control u˜ is given by
u˜(t) = min

1,max

0,
1
2
(
λ˜1(t)− λ˜5(t)− ν(t)
)
x˜1(t)
ω2



 ,
where the adjoint functions satisfy

˙˜λ1 = λ˜1
(
β
N
(x˜2 + ηC x˜3 + ηA x˜4) + µ+ u˜
)
−λ˜2
β
N
(x˜2 + ηC x˜3 + ηA x˜4)− λ˜5 u˜− ν u˜
˙˜
λ2 = −ω1 + λ˜1
β
N
x˜1 − λ˜2
(
β
N
x˜1 − ρ− φ− µ
)
− λ˜3 φ− λ˜4 ρ
˙˜λ3 = λ˜1
β
N
ηC x˜1 − λ˜2
(
β
N
ηC x˜1 + ω
)
− λ˜3 (−ω − µ)
˙˜
λ4 = λ˜1
β
N
ηAx˜1 − λ˜2
(
β
N
ηA x˜1 + α
)
− λ˜4 (−α− µ)
˙˜
λ5 = −λ˜1 θ − λ˜5 (−θ − µ) .
We solve the optimal control problem (17)–(20) numerically for concrete parameter
values and initial conditions. The initial conditions are given by (16) and the HIV
transmission parameters take the values β = 0.582, ηC = 0.04, and ηA = 1.35. We
assume that the default PrEP rate is equal to θ = 0.001 and the parameters ω,
ρ, φ, α take the values given by Table 2. The weight constants take the values
w1 = w2 = 1. We start by solving the optimal control problem without the mixed
state control constraint and compare the extremals with the case where the fraction
of individuals under PrEP is constant for all t ∈ [0, 25] and equal to ψ = 0.1 and
ψ = 0.9. In Figure 4, we observe that the number of HIV-infected individuals
associated with the optimal control solution I˜, C˜, A˜ is lower than the respective
number associated with the constant values ψ = 0.1 or ψ = 0.9. On the other hand,
we observe that the optimal control starts taking the maximum value 1, which
means that all susceptible individuals should be under PrEP (see Figure 5a) but
this situation does not respect the mixed state control constraint (see Figure 5b)
and implies higher implementation costs. Now, consider the mixed state-control
constraint
S(t)u(t) ≤ 2000 , ϑ ≥ 0 , for almost all t ∈ [0, tf ]. (21)
We start by comparing the optimal control solutions I˜, C˜, A˜ and E˜ associated
with the optimal control u˜ with the solution of model (10) with fixed values for
the fraction of susceptible individuals under PrEP, ψ = 0.1, 0.9. In Figure 6, we
observe that optimal control solutions are not associated with the lowest values
of the number of individuals with HIV infection. In fact, if we consider the case
where 90 per cent of the susceptible population is under PrEP, the number of
individuals with HIV infection is lower than the corresponding values associated
with the optimal control solution. This is related to the mixed constraint (21). In
Figure 7b, we observe that the mixed constraint (21) is satisfied for all t ∈ [0, 25].
The optimal control u˜ starts with the value 0.2 and is an increasing function for
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solution of model (10) for ψ = 0.1, the dashed line “−−” is the
solution of the optimal control problem with no mixed state control
constraint and “· −” is the solution of model (10) for ψ = 0.9.
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Figure 5. Solutions of the optimal control problem with no mixed
state control constraint. (a) Optimal control. (b) Total number of
individuals that take PrEP at each instant of time.
t ∈ [0, 4.05] years; for t ∈ [4.05, 6.88], the optimal control u˜ takes the maximum value
one, which means that all susceptible individuals should be taking PrEP. For the
rest of the simulation period, the optimal control u˜ is a decreasing function, taking
MODELING AND OPTIMAL CONTROL OF HIV/AIDS 19
0 10 20 30
0
2000
4000
6000
8000
10000
time (years)
E
 
 
ψ = 0.1
OC
ψ = 0.9
0 10 20 30
0
50
100
150
200
time (years)
I
 
 
ψ = 0.1
OC
ψ = 0.9
0 10 20 30
0
200
400
600
800
time (years)
C
 
 
ψ = 0.1
OC
ψ = 0.9
0 10 20 30
0
10
20
30
time (years)
A
 
 
ψ = 0.1
OC
ψ = 0.9
Figure 6. Top left: Individuals under PrEP, E. Top right: pre-
AIDS HIV infected individuals, I. Bottom left: HIV-infected in-
dividuals under ART treatment, C. Bottom right: HIV-infected
individuals with AIDS symptoms, A. The continuous line is the
solution of model (10) for ψ = 0.1, the dashed line “−−” is the so-
lution of the optimal control problem with the mixed state control
constraint (21) and “· −” is the solution of model (10) for ψ = 0.9.
values less than one. The mean value of the optimal control is approximately 0.61
(see Figure 7a). In Figure 8, we simulate the case where the fraction of susceptible
individuals under PrEP is constantly equal to the mean value of the optimal control
u˜, that is, ψ = 0.61, and compare the solutions of model (10) with the solutions of
the optimal control problem with mixed state control constraint. We observe that
the number of HIV infected individuals is lower for ψ = 0.61 than the ones associated
with the optimal control solutions. However, the total number of individuals under
PrEP at each instant of time is much bigger for ψ = 0.61 (see Figure 7c). In fact, we
have
∫ 25
0 u˜(t)S˜(t)dt = 12553 and
∫ 25
0 0.61S(t)dt = 13201, where S(t) denotes the
solution of model (10) for ψ = 0.61. We conclude that the cost associated with the
PrEP strategy ψ = 0.61 is bigger than the one associated with the optimal control
strategy. On the other hand, for the optimal control problem with no mixed state
control constraint, we have
∫ 25
0
u˜(t)S˜(t)dt = 12836, which means that this solution
has a bigger cost than the one that satisfies the mixed constraint.
Let us now suppose that we increase the value of w2, that is, the weight associated
with the cost of submitting susceptible individuals to PrEP. An increase of w2 is
associated with a decrease of the number of individuals that will be under PrEP.
For example, for w2 = 10000, the maximum value of the optimal control u˜ is
approximately 0.17 and
∫ 25
0 u˜(t)S˜(t)dt = 6652.5, that is, the cost associated with
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Figure 7. (a) Optimal control u˜ considering the mixed state con-
trol constraint (21). (b) Total number of individuals under PrEP
at each instant of time for t ∈ [0, 25] associated with the optimal
control u˜. (c) Total number of individuals under PrEP at each
instant of time for t ∈ [0, 25] associated with ψ = 0.61.
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Figure 8. Extremals of the optimal control problem (17)–(20)
with θ = 0.001.
the PrEP strategy decreases significantly. However, the number of HIV-infected
individuals increases, namely I˜(25) ≃ 110, C˜(25) ≃ 813 and A˜(25) ≃ 29.
5. Conclusion and future work. We have proved the global stability of the en-
demic equilibrium point of the SICA model for HIV/AIDS transmission proposed in
[30], in the case where the AIDS-induced death rate is negligible. Two different val-
ues for the relative infectiousness of HIV-infected individuals under ART treatment
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were considered, based on the studies reported in [9, 11] (ηC = 0.04 and ηC = 0.015)
and two values for the relative infectiousness of HIV-infected individuals with AIDS
symptoms (ηA = 1.3 and ηA = 1.35), based in [37]. We have shown that taking the
parameter values given in Table 2, the SICA model describes well the cumulative
cases of infection by HIV and AIDS in Cape Verde for the period from 1987 to 2014
[25, 42]. Furthermore, we generalized the SICA model to a HIV/AIDS-PrEP model
(SICAE model) including PrEP as an HIV prevention strategy. We proved the exis-
tence and uniqueness of disease-free and endemic equilibrium points, depending on
the value of the basic reproduction number R0. Through Lyapunov functions and
LaSalle’s Invariance Principle, we proved the global stability of the disease-free equi-
librium for R0 < 1 and the global stability of the endemic equilibrium point when
R0 > 1 for negligible AIDS-induced death rate and strict adherence to PrEP. The
number of HIV-infected individuals for the SICA and SICAE models was compared.
We concluded that PrEP reduces the number of new HIV infections. However, only
people who are HIV-negative and at very high risk for HIV infection should take
PrEP. Therefore, the number of individuals that should take PrEP must be limited
at each instant of time, for a fixed interval of time. In order to study this health
public problem, we formulated an optimal control problem with a mixed state con-
trol constraint, where the objective is to determine the optimal PrEP strategy that
satisfies the mixed constraint (the total number of individuals under PrEP at each
instant of time is limited) and minimizes the number of pre-AIDS HIV-infected
individuals as well as the cost associated with the implementation of PrEP. The
optimal control problems with and without the mixed state control constraint were
solved and compared with the optimal solutions in the case where the fraction of
individuals under PrEP is constant. Optimal control theory gave us PrEP strate-
gies that minimize the number of HIV-infected individuals, the cost associated with
PrEP and satisfy the limitations on the number of total individuals that should be
under PrEP at each instant of time.
It remains open the questions of how to prove the global stability of the endemic
equilibrium point of the SICA model for positive AIDS-induced death rate and of
the SICAE model for positive AIDS-induced death and PrEP default rates. As for
the optimal control problem with mixed state control constraint, we believe it will be
also interesting to consider a L1 cost functional and a variable total population size.
These and other questions are under investigation and will be addressed elsewhere.
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